BioStem Technologies Inc. (OTC:BSEM) Stock Gains Momentum: Now What
The leading regenerative medicine company, BioStem Technologies Inc. (OTC:BSEM), is involved in the development, commercialization, and manufacturing of placental allografts meant for high-end wound care. On May 6, the company learned that its request for Prioritized Examination for BioStem Technologies’ United States patent for STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF had been granted by the United States Patent and Trademark Office. The Chief Executive Officer of the company, Jason Matuszewski, spoke about the latest development yesterday.
He stated that as BioStem Technologies continued to work on the expansion of its product portfolio in vital areas of care, everyone at the company was pleased at the fact that another move had been made to protect its intellectual property. He went on to state that the patent in question related to the proprietary BioREtain processing of the company and that it anchored the product technology overall. The proprietary asset differentiated BioStem Technologies from its competitors in the industry and also helped the company provide top-of-the line wound care. He concluded by stating that the company was looking forward to collaborating with the USPTO as the application went through the priority examination process.
Upon the award of the patent, the company’s method for human amniotic tissue processing would be protected. In this context, it is perhaps also important to note that the worldwide wound care dressing market was valued at $14.20 billion last year. From 2024 until 2030, the industry is projected to grow at a rate of 4.16% CAGR. BioStem Technologies is best known as a company that is involved in the manufacturing of products that change lives for the better through the deployment of its BioREtain processing methodology. In light of the latest developments, it could be a good time for investors to keep an eye on the stock.
